Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lappaconitine is a natural diterpene alkaloid originally isolated from Aconitum sinomontanum (sacred tower giant Chinese monkshood), a plant used in traditional Chinese medicine. It acts primarily as a voltage-gated sodium channel blocker, distinguishing it from other aconitum alkaloids like aconitine, which are sodium channel activators[1][2][6]. Lappaconitine exhibits multiple pharmacological activities including analgesic, anti-inflammatory, antiarrhythmic (class IC), antiepileptic/anticonvulsant, and antitumor effects[2][3][7]. Its analgesic effect is non-opioid in nature and has been shown to be effective for moderate to severe pain management such as cancer pain and postoperative pain[3][6]. The compound also downregulates P2X3 receptor expression in dorsal root ganglion neurons and modulates inflammatory cytokines via the NF-kB and MAPK pathways[2][3]. Clinically, lappaconitine or its hydrobromide salt has been used mainly in China for arrhythmias and as an analgesic agent; however, its development for arrhythmia was discontinued after phase II trials due to efficacy or safety concerns[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lappaconitine.